A failure to obtain informed consent lawsuit occurs when a healthcare provider or clinical researcher proceeds with treatment or medical procedures without properly obtaining a patient’s knowing and voluntary agreement. This type of lawsuit is rooted in a fundamental principle of medical ethics and law: patients have the right to understand the risks, benefits, and alternatives of any medical intervention before agreeing to it. When doctors or medical institutions skip this critical step or provide incomplete information, they may face significant legal liability, including class-action settlements.
In 2026 alone, we’ve seen multiple cases highlighting this issue, from a major lawsuit filed in California against Sutter Health and MemorialCare for allegedly recording patient-doctor conversations with AI technology without clear informed consent, to ongoing federal cases challenging government health agencies’ disclosure practices. The legal framework for informed consent requires four essential elements to be proven in a lawsuit: (1) a doctor-patient relationship must have existed, (2) the healthcare provider failed to disclose critical information about risks, benefits, or alternatives, (3) the patient would have made a different decision if properly informed, and (4) the patient suffered actual harm as a result of proceeding without that informed consent. These requirements apply across medical settings—from routine surgeries to experimental drug trials—and the consequences for violations can include compensatory damages, punitive damages, and systemic changes to how institutions handle patient disclosure.
Table of Contents
- What Constitutes a Violation of Informed Consent?
- The Duty to Disclose and Its Legal Limits
- Informed Consent in Clinical Trials and Medical Research
- Class Action Settlements for Informed Consent Violations
- Establishing Causation and Harm
- Damages and Remedies in Informed Consent Litigation
- The Evolving Landscape of Informed Consent in the Digital Age
- Conclusion
What Constitutes a Violation of Informed Consent?
The legal standard for informed consent isn’t simply about having a patient sign a form. Courts have established that informed consent requires three critical components: disclosure of relevant information, the patient’s actual understanding of that information, and a truly voluntary decision without coercion or undue influence. This means a doctor cannot hide behind a lengthy, technical consent form that patients don’t actually comprehend. If a healthcare provider discusses only the benefits of a treatment while downplaying or omitting significant risks, that’s a violation even if the patient signed something. In clinical trials, this becomes even more rigorous—researchers must clearly explain the experimental nature of treatment, potential side effects that are unknown, and the patient’s right to withdraw at any time without penalty.
One of the most striking examples illustrating this issue is the recent California case filed on April 10, 2026, in San Francisco federal court. Multiple Californians sued Sutter Health and MemorialCare, alleging that these healthcare systems recorded patient-doctor conversations using artificial intelligence technology without obtaining clear informed consent from patients. The plaintiffs argued that while patients may have signed general consent forms, they had no specific knowledge that AI was analyzing their private medical conversations. This case demonstrates that consent must be specific and contextual—blanket permission for “medical recordkeeping” does not automatically extend to emerging technologies like AI surveillance. The distinction is crucial: patients might willingly consent to traditional record-keeping but refuse AI analysis, making the omission of that detail a violation of their informed consent rights.
The Duty to Disclose and Its Legal Limits
Healthcare providers operate under what’s called the “duty to disclose,” which varies by jurisdiction but generally requires doctors to share information that a reasonable patient would want to know before making a medical decision. Some states follow a “reasonable physician standard” (what other doctors would typically disclose), while others apply a “reasonable patient standard” (what information a typical patient would need to make an informed decision). The reasonable patient standard is generally more protective of patients because it acknowledges that patients need to know things even if doctors commonly leave them out. However, one important limitation exists: the “therapeutic privilege” allows doctors to withhold certain information if they believe disclosure would cause serious psychological harm to the patient. This exception is narrowly applied, and courts scrutinize it carefully—it cannot be used simply because a doctor thinks a patient won’t understand or might worry about hearing the truth.
A critical warning for patients: the duty to disclose applies specifically to “material” risks—those that are significant enough that a reasonable person would want to know about them. Minor risks that rarely occur and have minimal consequences may not need to be disclosed. However, the definition of “material” can become a central battle point in litigation. For instance, if a surgical procedure carries even a small risk of permanent disability, that’s material. But if a treatment has a 0.001% chance of a specific side effect, a doctor might argue it’s not material enough to require disclosure. This gray area is where many informed consent disputes arise, and patients often lose these battles because they must prove the risk was material—the burden is on the plaintiff to show that a reasonable person would have wanted to know.
Informed Consent in Clinical Trials and Medical Research
Clinical trials and experimental medical research have the highest informed consent standards because patients are often testing unproven treatments with unknown risks. Federal regulations require that clinical trial consent forms explicitly state that participation is voluntary, explain the purpose of the research, describe foreseeable risks and benefits, disclose alternative procedures or treatments, and explain what compensation and medical treatment are available if injury occurs. Additionally, researchers must inform participants of whom to contact with questions and must clearly state that participation is completely voluntary and can be terminated at any time without penalty. This is far more stringent than the consent required for standard medical treatment, reflecting the elevated risk inherent in experimental medicine. Recent federal cases have tested these standards. The Informed Consent Action Network filed multiple lawsuits against federal health agencies regarding disclosure practices. In one case decided February 5, 2026 (Case No.
25-00832 in D.C. Federal Court), and another on February 12, 2026 (Case No. 24-1905), courts partially granted and partially denied motions in these informed consent disputes. These cases underscore that informed consent issues extend beyond individual doctors and hospitals to questions about how government agencies and large-scale research programs obtain and maintain patient consent. Another case from March 3, 2026 (Case No. 23-926) involved questions about COVID-19 genetic sequencing data and whether proper informed consent was obtained for how genetic information was used. The court’s decision in that case demonstrates that informed consent applies not just to the initial medical procedure but also to how patient data and biological materials are used downstream.
Class Action Settlements for Informed Consent Violations
When informed consent violations affect large numbers of patients, they often become class-action lawsuits, with settlements that can reach millions of dollars. In a class-action framework, one or more patients sue on behalf of all patients who were similarly harmed by the same conduct. These cases are particularly valuable for plaintiffs because they allow the cost of litigation to be spread across many claimants, making it economically feasible to pursue cases against large healthcare systems that would be too expensive to litigate individually. Settlements in informed consent class actions typically include monetary compensation for affected patients, establishment of fund for medical monitoring, and requirements that the defendant institution implement new consent procedures and provide enhanced disclosure to patients going forward.
One important tradeoff to understand: class-action settlements often provide compensation to all class members even if some individuals suffered more harm than others. This is efficient from an administrative standpoint—courts and claims administrators don’t have to evaluate thousands of individual injury claims—but it means individual recovery is typically lower than what a successful individual lawsuit might yield. Additionally, class members often cannot opt out if they want to pursue their own case against the institution, though they can usually request exclusion from the settlement if they decide to sue separately. For patients considering whether to join an informed consent class action, the decision comes down to whether the guaranteed recovery (even if modest) is preferable to the risk and uncertainty of individual litigation.
Establishing Causation and Harm
One of the most challenging elements to prove in an informed consent case is establishing causation—that the lack of informed consent actually caused the patient’s harm. Plaintiffs must convince a court that if they had been properly informed, they would have rejected the treatment or made a different decision. This requires presenting evidence about what the patient would have chosen, which is inherently speculative. Defendants argue that many patients would have consented anyway even with full disclosure, or that the harm resulted from the treatment itself, not from the failure to disclose information.
Some courts require plaintiffs to show what’s called “subjective causation”—that this particular patient would have refused treatment if informed—while others allow “objective causation” evidence, using reasonable patient standards to infer what a reasonable person would have done. A significant warning: expert testimony becomes crucial in these cases, and expert witnesses for both sides will often offer competing opinions about what the standard of care required and whether adequate disclosure occurred. The defendant’s medical experts may testify that the disclosure was adequate by the standards of their profession, while the plaintiff’s experts argue it fell short. Additionally, if a patient delayed in filing the lawsuit, defendants often argue that the patient’s failure to immediately object or seek a second opinion suggests they weren’t truly upset about the lack of informed consent. Time delays can seriously undermine these claims because judges may question whether the patient really would have made a different choice had they known—if the patient didn’t immediately challenge the doctor’s actions upon learning the truth, why should the court believe the patient’s current claim about what they would have done?.
Damages and Remedies in Informed Consent Litigation
When plaintiffs successfully prove an informed consent violation, they can recover compensatory damages for actual harm suffered. This includes past and future medical expenses related to treating injury caused by the unwanted procedure, lost wages due to pain, suffering, and disability, and pain and suffering damages for the emotional distress caused by the violation itself. In some cases, courts also award punitive damages—extra money designed to punish the defendant and deter similar conduct in the future—particularly when the healthcare provider’s conduct was egregious or involved intentional deception. Some jurisdictions also recognize damages for the violation itself, sometimes called “dignitary damages,” compensating patients for the violation of their right to make autonomous medical decisions, regardless of physical harm.
Beyond monetary compensation, many informed consent settlements include injunctive relief—court orders requiring the defendant institution to change its practices. For example, a settlement might require Sutter Health and MemorialCare to implement new policies requiring specific consent forms for AI recording of patient conversations, to provide staff training on informed consent requirements, or to allow patient education periods before consent is solicited. These systemic changes often have broader impact than individual compensation because they affect how the institution treats all future patients. In the California AI recording case filed in April 2026, patients are not only seeking monetary damages for their own recorded conversations but likely seeking institutional reforms to prevent this from happening to future patients.
The Evolving Landscape of Informed Consent in the Digital Age
The California case involving Sutter Health and MemorialCare highlights a forward-looking issue in informed consent litigation: how do existing legal standards apply to emerging technologies? Artificial intelligence, genetic analysis, digital health records, and telemedicine all raise new questions about what disclosure is required and what patients need to understand about their medical care. Traditional informed consent doctrine developed in an era when doctors and patients met in person and treatment happened in relatively straightforward ways. Now, medical institutions are using patient data for secondary purposes—training AI models, selling anonymized data to researchers, using genetic information for population studies—that patients may not anticipate or understand.
Courts and regulators are still developing frameworks for how informed consent applies to these new contexts. The federal cases filed by the Informed Consent Action Network against the FDA and NIH in 2025 and 2026 show that even government agencies face questions about adequate disclosure of how patient information is used. As technology continues advancing faster than legal doctrine, patients should expect informed consent litigation to increasingly focus on data use, algorithmic decision-making, and the scope of what patients should know about how their medical information will be leveraged. Healthcare providers and researchers who fail to adapt their consent practices to address these emerging issues will likely face litigation, and class actions may become more common as patients recognize that they’ve consented to treatment without understanding how their data will be used.
Conclusion
A failure to obtain informed consent lawsuit holds healthcare providers accountable for violating one of medicine’s most fundamental principles: that patients have the right to understand and approve of what is done to their bodies. These lawsuits can arise from simple omissions—a doctor discussing benefits but not mentioning risks—or from complex modern scenarios like using AI to analyze medical conversations without explicit consent. The legal requirements are clear: patients must receive material information, understand it, and make a voluntary decision.
When healthcare providers fall short of this standard, they face liability, and when multiple patients are affected by the same conduct, class-action settlements can provide compensation and force institutional change. If you believe you may have been a victim of inadequate informed consent, documenting what you were told, what you were not told, and what harm resulted is crucial. Consulting with a medical malpractice or informed consent attorney can help you understand whether you have a viable claim. For those considering joining an informed consent class-action lawsuit, reviewing the settlement terms and claims process carefully will help you determine whether participation aligns with your individual circumstances and preferences.